YOU STOPPED AT: Scenario 2: PSA Continues Rising (0.008-0.015 ng/mL) Finding Interpretation Action PSA value 0.008-0

Scenario 2: PSA Continues Rising (0.008-0.015 ng/mL)

What This Result Means

| Finding | Interpretation | Action | |---|---|---| | PSA value | 0.008-0.015 ng/mL | ⚠️ Concerning trend | | What it means | The rise from 0.004 → 0.007 → 0.008-0.015 suggests a real PSA trend, NOT assay variability | Increase monitoring frequency | | PSADT relevance | PSADT calculation is still unreliable at these low values, BUT the direction of trend is now meaningful | Don't rely on calculated PSADT; focus on trajectory | | Biochemical recurrence status | Still NO BCR (BCR requires PSA >0.1 ng/mL) | You remain in excellent prognostic category | | Next step | PSA every 3 months (not 6 months) | Closer monitoring to clarify trajectory | | Prognosis | Still excellent — 85-90% 5-year BCRFS maintained | Early detection allows optimal timing of salvage therapy |

---

Why This Scenario Requires Closer Monitoring

The Clinical Reasoning

According to NCCN Guidelines (2025), AUA Guidelines (2023), and EAU Guidelines (2023):

When you have 3 rising PSA values (0.004 → 0.007 → 0.008-0.015):

1. A real trend is emerging

   • ✅ Three consecutive rising values = pattern, not noise
   • ✅ Assay variability alone is unlikely to cause 3 consecutive rises
   • ✅ This suggests early biochemical recurrence (BCR) is developing

2. You're still in an excellent window for intervention

   • ✅ PSA is still <0.1 ng/mL (undetectable range)
   • ✅ Early detection at low PSA = better salvage therapy outcomes
   • ✅ This is the IDEAL time to catch recurrence before it becomes aggressive

3. Closer monitoring helps determine next steps

   • ✅ PSA every 3 months will clarify the rate of rise
   • ✅ Once you have 4-5 values, PSADT becomes more reliable
   • ✅ This data guides timing of imaging and salvage therapy

Source: NCCN Guidelines (2025) — PSA kinetics and BCR detection; AUA Guidelines (2023) — Post-operative surveillance protocols; EAU Guidelines (2023) — Early detection of recurrence

---

Your Monitoring Plan: If PSA Continues Rising

What to Expect Over the Next 6-12 Months

If your PSA continues rising in the 0.008-0.015 range:

| Time Point | Recommended Action | Purpose | |---|---|---| | Now (384 days post-op) | PSA = 0.008-0.015 ng/mL | Confirm rising trend | | In 3 months (474 days post-op) | Repeat PSA test | Assess rate of rise | | In 6 months (564 days post-op) | Repeat PSA test | Clarify trajectory | | In 9 months (654 days post-op) | Repeat PSA test | Determine if imaging needed | | If PSA approaches 0.1 ng/mL | PSMA-PET scan | Detect metastatic disease | | If PSA >0.1 ng/mL or rapid rise | Oncology consultation | Plan salvage therapy |

---

When to Consider Imaging (PSMA-PET Scan)

Imaging Thresholds According to Guidelines

According to NCCN Guidelines (2025), AUA Guidelines (2023), and EAU Guidelines (2023):

PSMA-PET imaging is typically recommended when:

| Trigger | PSA Level | Action | |---|---|---| | PSA threshold | PSA ≥0.1 ng/mL | PSMA-PET scan indicated | | Rapid PSA rise | PSA doubling time <3 months | PSMA-PET scan indicated | | Clinical symptoms | Bone pain, urinary symptoms | PSMA-PET scan indicated | | Your current status | PSA 0.008-0.015 ng/mL | Not yet at imaging threshold |

Your situation:

• ✅ PSA is still <0.1 ng/mL (below imaging threshold)
• ✅ PSA doubling time is slow (~9-10 months, though unreliable)
• ✅ No clinical symptoms reported
• ✅ Imaging is NOT recommended yet

When imaging becomes appropriate:

• ⚠️ If PSA reaches 0.1 ng/mL
• ⚠️ If PSA doubling time becomes <3 months (after 4-5 values)
• ⚠️ If you develop symptoms (bone pain, urinary changes)

Source: NCCN Guidelines (2025) — PSMA-PET imaging indications; AUA Guidelines (2023) — Imaging thresholds for BCR

---

Salvage Therapy Options: What You Should Know

If PSA Continues Rising and Imaging Confirms Recurrence

According to NCCN Guidelines (2025), AUA Guidelines (2023), and EAU Guidelines (2023):

For favorable intermediate risk patients with rising PSA after prostatectomy, salvage therapy options include:

| Option | Timing | Success Rate | Side Effects | |---|---|---|---| | Salvage radiation therapy (SRT) | PSA 0.1-0.5 ng/mL | 60-70% 5-year BCRFS | Urinary/bowel toxicity, erectile dysfunction | | Salvage hormone therapy (ADT) | PSA 0.1-0.5 ng/mL | 50-60% 5-year BCRFS | Hot flashes, fatigue, sexual dysfunction | | Salvage SRT + ADT | PSA 0.1-0.5 ng/mL | 70-80% 5-year BCRFS | Combined side effects | | Clinical trials | Variable | Variable | Depends on trial |

Key principle: Earlier salvage therapy (at lower PSA) generally has better outcomes.

Your advantage: If you're detected early (PSA 0.1-0.2 ng/mL), you have the best chance of successful salvage therapy.

Source: NCCN Guidelines (2025) — Salvage therapy for BCR; AUA Guidelines (2023) — Timing and outcomes of salvage therapy

---

Questions to Ask Your Oncologist

If Your PSA Continues Rising

1. "Based on my rising PSA trend, when would you recommend PSMA-PET imaging?"

   • ✅ Expected answer: When PSA reaches 0.1 ng/mL or if doubling time becomes <3 months
   • ✅ Ask for: Specific PSA threshold for your case

2. "What is my current PSA doubling time, and how reliable is it at these low values?"

   • ✅ Expected answer: PSADT is unreliable at PSA <0.1 ng/mL; focus on trend direction instead
   • ✅ Ask for: Confirmation that they're NOT basing decisions solely on PSADT

3. "If imaging shows recurrence, what are my salvage therapy options?"

   • ✅ Expected answer: Salvage radiation therapy ± hormone therapy, depending on imaging findings
   • ✅ Ask for: Success rates, side effects, and timing of treatment

4. "What is the advantage of treating early (at lower PSA) versus waiting?"

   • ✅ Expected answer: Earlier treatment at lower PSA generally has better outcomes
   • ✅ Ask for